Product was Celularity’s largest product and service line in fiscal 2025, bringing in $13.18M of $26.55M (50%).
| Product and Service | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Product | — | $13.15M | $35.34M | $13.18M | ||
| Product Sales | $3.75M | — | — | — | ||
| Product Sales & Rentals | — | — | — | — | ||
| License Royalty & Other | — | $4.18M | $13.74M | $7.94M | ||
| License, Royalty & Other | $8.71M | — | — | — | ||
| Service | — | $5.44M | $5.14M | $5.43M | ||
| Services | $5.51M | — | — | — | ||
| Total | $17.98M | $22.77M | $54.22M | $26.55M |
Celularity brought in $26.55M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 51.0% from $54.22M in fiscal 2024. Product was the largest at $13.18M (49.6%), ahead of License Royalty & Other at $7.94M (29.9%) and Service at $5.43M (20.5%).
Compared with fiscal 2024, Service grew fastest, up 5.7% to $5.43M, while Product fell the most, down 62.7% to $13.18M.
Celularity began breaking out Product in fiscal 2023, License Royalty & Other in fiscal 2023 and Service in fiscal 2023. Celularity stopped reporting License, Royalty & Other ($8.71M in fiscal 2022), Services ($5.51M in fiscal 2022) and Product Sales ($3.75M in fiscal 2022) as separate lines.
Degenerative Disease was Celularity’s largest segment in fiscal 2025, bringing in $17.31M of $26.55M (65%).
| Segment | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Degenerative Disease | $12.46M | $17.33M | $48.39M | $17.31M | ||
| Biobanking | $5.51M | $5.44M | $5.14M | $5.43M | ||
| Cell Therapy | — | — | $688.00K | $3.81M | ||
| Total | $17.98M | $22.77M | $54.22M | $26.55M |
Celularity brought in $26.55M from its three segments in fiscal 2025, the year ended December 31, 2025. That was down 51.0% from $54.22M in fiscal 2024. Degenerative Disease was the largest at $17.31M (65.2%), ahead of Biobanking at $5.43M (20.5%) and Cell Therapy at $3.81M (14.3%).
Compared with fiscal 2024, Cell Therapy grew fastest, up 453.3% to $3.81M, while Degenerative Disease fell the most, down 64.2% to $17.31M.
Celularity began breaking out Cell Therapy in fiscal 2024, when it brought in $688.00K.
Celularity (CELU) reports its revenue by product and service and by segment. In fiscal 2025, Product was its largest product and service line, bringing in $13.18M (49.6% of the total), followed by License Royalty & Other at $7.94M (29.9%).
Product was Celularity's largest product and service line in fiscal 2025, bringing in $13.18M, or 49.6% of the $26.55M total across its three product and service lines.
Degenerative Disease was Celularity's largest segment in fiscal 2025, bringing in $17.31M, or 65.2% of the $26.55M total across its three segments.
Among Celularity's product and service lines that make up at least 2% of revenue, Service grew fastest in fiscal 2025, up 5.7% from $5.14M to $5.43M.
Every figure comes from Celularity's annual financial filings, as reported. Each line keeps the name Celularity gives it, and years follow its fiscal calendar.
Celularity's revenue by product and service goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.